Markus Warmuth
Chief Executive Officer
Oncology Drug Discovery
H3 Biomedicine
United States of America
Biography
Dr. Markus Warmuth became President and Chief Executive Officer of H3 Biomedicine in 2011 and is responsible for the overall scientific and business direction of the company. Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site where he led a significant portion of NIBR’s global oncology drug discovery portfolio.
Research Interest
Drug Discovery
